{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:34:33Z","timestamp":1760189673275},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s11864-019-0605-x","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T06:15:58Z","timestamp":1549260958000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Blastic Plasmacytoid Dendritic Cell Neoplasm"],"prefix":"10.1007","volume":"20","author":[{"suffix":"II","given":"Daniel","family":"Kerr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"issue":"20","key":"605_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. \n                      https:\/\/doi.org\/10.1182\/blood-2016-03-643544\n                      \n                    .","journal-title":"Blood"},{"issue":"1","key":"605_CR2","first-page":"58","volume":"89","author":"C Bueno","year":"2004","unstructured":"Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, et al. Incidence and characteristics of CD4(+)\/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58\u201369.","journal-title":"Haematologica"},{"issue":"4","key":"605_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/107327481402100404","volume":"21","author":"W Riaz","year":"2014","unstructured":"Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21(4):279\u201389. \n                      https:\/\/doi.org\/10.1177\/107327481402100404\n                      \n                    .","journal-title":"Cancer Control"},{"issue":"4","key":"605_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00277-018-3259-z","volume":"97","author":"S Wang","year":"2018","unstructured":"Wang S, Wang X, Liu M, Bai O. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents. Ann Hematol. 2018;97(4):563\u201372. \n                      https:\/\/doi.org\/10.1007\/s00277-018-3259-z\n                      \n                    .","journal-title":"Ann Hematol"},{"issue":"5","key":"605_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/PAS.0000000000000156","volume":"38","author":"F Julia","year":"2014","unstructured":"Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N, et al. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 2014;38(5):673\u201380. \n                      https:\/\/doi.org\/10.1097\/PAS.0000000000000156\n                      \n                    .","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"605_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239\u201346. \n                      https:\/\/doi.org\/10.3324\/haematol.2012.072645\n                      \n                    .","journal-title":"Haematologica"},{"key":"605_CR7","unstructured":"Swerdlow S, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H, Thiele, J, Vardiman, JW. WHO Classification of tumours of haematopoietic and lymphoid tissues, Fourth Edition 2008. 439"},{"issue":"1","key":"605_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/asheducation-2016.1.16","volume":"2016","author":"JM Sullivan","year":"2016","unstructured":"Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016;2016(1):16\u201323. \n                      https:\/\/doi.org\/10.1182\/asheducation-2016.1.16\n                      \n                    .","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"605_CR9","doi-asserted-by":"publisher","first-page":"10174","DOI":"10.18632\/oncotarget.7101","volume":"7","author":"L Martin-Martin","year":"2016","unstructured":"Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9):10174\u201381. \n                      https:\/\/doi.org\/10.18632\/oncotarget.7101\n                      \n                    .","journal-title":"Oncotarget"},{"issue":"9","key":"605_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/13543784.2018.1512970","volume":"27","author":"D Kerr 2nd","year":"2018","unstructured":"Kerr D 2nd, Sokol L. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm. Expert Opin Investig Drugs. 2018;27(9):733\u20139. \n                      https:\/\/doi.org\/10.1080\/13543784.2018.1512970\n                      \n                    .","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"605_CR11","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","volume":"99","author":"J Feuillard","year":"2002","unstructured":"Feuillard J, Jacob MC, Valensi F, Maynadi\u00e9 M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556\u201363.","journal-title":"Blood"},{"issue":"7","key":"605_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bmt.1704215","volume":"32","author":"P Reimer","year":"2003","unstructured":"Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637\u201346. \n                      https:\/\/doi.org\/10.1038\/sj.bmt.1704215\n                      \n                    .","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"605_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/ajh.24258","volume":"91","author":"U Deotare","year":"2016","unstructured":"Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol. 2016;91(3):283\u20136. \n                      https:\/\/doi.org\/10.1002\/ajh.24258\n                      \n                    .","journal-title":"Am J Hematol"},{"issue":"4","key":"605_CR14","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.leukres.2009.09.006","volume":"34","author":"NJ Tsagarakis","year":"2010","unstructured":"Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res. 2010;34(4):438\u201346. \n                      https:\/\/doi.org\/10.1016\/j.leukres.2009.09.006\n                      \n                    .","journal-title":"Leuk Res"},{"issue":"7","key":"605_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/pbc.20034","volume":"42","author":"N Hyakuna","year":"2004","unstructured":"Hyakuna N, Toguchi S, Higa T, Okudaira T, Taira N, Masuda M, et al. Childhood blastic NK cell leukemia successfully treated with L-asparagenase and allogeneic bone marrow transplantation. Pediatr Blood Cancer. 2004;42(7):631\u20134. \n                      https:\/\/doi.org\/10.1002\/pbc.20034\n                      \n                    .","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"605_CR16","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3904\/kjim.2015.406","volume":"32","author":"HS Kim","year":"2017","unstructured":"Kim HS, Kim HJ, Kim SH, Choi JY, Ko YH, Kim WS, et al. Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea. Korean J Intern Med. 2017;32(5):890\u20139. \n                      https:\/\/doi.org\/10.3904\/kjim.2015.406\n                      \n                    .","journal-title":"Korean J Intern Med"},{"issue":"8","key":"605_CR17","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3109\/10428194.2012.656627","volume":"53","author":"L Gilis","year":"2012","unstructured":"Gilis L, Lebras L, Bouafia-Sauvy F, Espinouse D, Felman P, Berger F, et al. Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+\/CD56+ hematodermic neoplasm. Leuk Lymphoma. 2012;53(8):1633\u20137. \n                      https:\/\/doi.org\/10.3109\/10428194.2012.656627\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"605_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/bjh.12523","volume":"163","author":"B Gruson","year":"2013","unstructured":"Gruson B, Vaida I, Merlusca L, Charbonnier A, Parcelier A, Damaj G, et al. L-asparaginase with methotrexate and dexamethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2013;163(4):543\u20135. \n                      https:\/\/doi.org\/10.1111\/bjh.12523\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"5","key":"605_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.14954","volume":"179","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Al Malki MM, Deotare U, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a north American multicentre collaborative study. Br J Haematol. 2017;179(5):781\u20139. \n                      https:\/\/doi.org\/10.1111\/bjh.14954\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"3","key":"605_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","volume":"121","author":"D Roos-Weil","year":"2013","unstructured":"Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440\u20136. \n                      https:\/\/doi.org\/10.1182\/blood-2012-08-448613\n                      \n                    .","journal-title":"Blood"},{"issue":"23","key":"605_CR21","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","volume":"125","author":"T Aoki","year":"2015","unstructured":"Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125(23):3559\u201362. \n                      https:\/\/doi.org\/10.1182\/blood-2015-01-621268\n                      \n                    .","journal-title":"Blood"},{"key":"605_CR22","doi-asserted-by":"publisher","first-page":"651906","DOI":"10.1155\/2011\/651906","volume":"2011","author":"A Steinberg","year":"2011","unstructured":"Steinberg A, Kansal R, Wong M, Lopez A, Lim S, Lopategui J, et al. Good clinical response in a rare aggressive hematopoietic neoplasm: plasmacytoid dendritic cell leukemia with no cutaneous lesions responding to 4 donor lymphocyte infusions following transplant. Case Rep Transplant. 2011;2011:651906. \n                      https:\/\/doi.org\/10.1155\/2011\/651906\n                      \n                    .","journal-title":"Case Rep Transplant"},{"issue":"6","key":"605_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/bmt.2012.242","volume":"48","author":"M Unteregger","year":"2013","unstructured":"Unteregger M, Valentin A, Zinke-Cerwenka W, Troppan K, Deutsch A, Cerroni L, et al. Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm. Bone Marrow Transplant. 2013;48(6):799\u2013802. \n                      https:\/\/doi.org\/10.1038\/bmt.2012.242\n                      \n                    .","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"605_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3324\/haematol.2009.010611","volume":"95","author":"R Gurion","year":"2010","unstructured":"Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. Haematologica. 2010;95(2):303\u201310. \n                      https:\/\/doi.org\/10.3324\/haematol.2009.010611\n                      \n                    .","journal-title":"Haematologica"},{"issue":"11","key":"605_CR25","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3109\/10428194.2016.1160084","volume":"57","author":"R Khwaja","year":"2016","unstructured":"Khwaja R, Daly A, Wong M, Mah\u00e9 E, Cerquozzi S, Owen C. Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases. Leuk Lymphoma. 2016;57(11):2720\u20132. \n                      https:\/\/doi.org\/10.3109\/10428194.2016.1160084\n                      \n                    .","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"605_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/ejh.12294","volume":"93","author":"K Laribi","year":"2014","unstructured":"Laribi K, Denizon N, Ghnaya H, Atlassi M, Besan\u00e7on A, Pineau-Vincent F, et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. Eur J Haematol. 2014;93(1):81\u20135. \n                      https:\/\/doi.org\/10.1111\/ejh.12294\n                      \n                    .","journal-title":"Eur J Haematol"},{"issue":"9","key":"605_CR27","first-page":"3493","volume":"6","author":"LM Krug","year":"2000","unstructured":"Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, et al. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000;6(9):3493\u20138.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"605_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00277-016-2907-4","volume":"96","author":"C Arranto","year":"2017","unstructured":"Arranto C, Tzankov A, Halter J. Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate. Ann Hematol. 2017;96(4):681\u20132. \n                      https:\/\/doi.org\/10.1007\/s00277-016-2907-4\n                      \n                    .","journal-title":"Ann Hematol"},{"issue":"3","key":"605_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jaad.2007.12.012","volume":"58","author":"JJ Leitenberger","year":"2008","unstructured":"Leitenberger JJ, Berthelot CN, Polder KD, Pro B, McLaughlin P, Jones D, et al. CD4+ CD56+ hematodermic\/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol. 2008;58(3):480\u20134. \n                      https:\/\/doi.org\/10.1016\/j.jaad.2007.12.012\n                      \n                    .","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"605_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/hon.2252","volume":"35","author":"S Betrian","year":"2017","unstructured":"Betrian S, Guenounou S, Luquet I, et al. Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia. Hematol Oncol. 2017;35(2):252\u20135. \n                      https:\/\/doi.org\/10.1002\/hon.2252\n                      \n                    .","journal-title":"Hematol Oncol"},{"key":"605_CR31","doi-asserted-by":"publisher","unstructured":"Ulrickson ML, Puri A, Lindstrom S, Cassaday RD, de Padova N, Becker PS. Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2017;92(5):E75\u2013E7. \n                      https:\/\/doi.org\/10.1002\/ajh.24696.28224664.","DOI":"10.1002\/ajh.24696.28224664."},{"issue":"8","key":"605_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/protein\/13.8.575","volume":"13","author":"AE Frankel","year":"2000","unstructured":"Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 2000;13(8):575\u201381.","journal-title":"Protein Eng"},{"issue":"4","key":"605_CR33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1021\/bc980015a","volume":"9","author":"AE Frankel","year":"1998","unstructured":"Frankel AE, Hall PD, McLain C, Safa AR, Tagge EP, Kreitman RJ. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Bioconjug Chem. 1998;9(4):490\u20136. \n                      https:\/\/doi.org\/10.1021\/bc980015a\n                      \n                    .","journal-title":"Bioconjug Chem"},{"issue":"1","key":"605_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/1568009023333944","volume":"2","author":"AE Frankel","year":"2002","unstructured":"Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets. 2002;2(1):19\u201336.","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"605_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.exphem.2003.11.005","volume":"32","author":"I Jedema","year":"2004","unstructured":"Jedema I, Barge RM, Frankel AE, Willemze R, Falkenburg JH. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor\/diphtheria toxin fusion proteins. Exp Hematol. 2004;32(2):188\u201394. \n                      https:\/\/doi.org\/10.1016\/j.exphem.2003.11.005\n                      \n                    .","journal-title":"Exp Hematol"},{"issue":"2","key":"605_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3324\/haematol.2014.111740","volume":"100","author":"F Angelot-Delettre","year":"2015","unstructured":"Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, et al. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica. 2015;100(2):223\u201330. \n                      https:\/\/doi.org\/10.3324\/haematol.2014.111740\n                      \n                    .","journal-title":"Haematologica"},{"issue":"3","key":"605_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","volume":"124","author":"AE Frankel","year":"2014","unstructured":"\u2022 Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385\u201392. \n                      https:\/\/doi.org\/10.1182\/blood-2014-04-566737\n                      \n                    This was the first trial reporting activity for SL-401. All of these patients had relapsed\/refractory disease and most received only 1 cycle of therapy. Despite the minimal therapy, there was still a 55% CR rate with some very durable responses (ie., 20+ months).","journal-title":"Blood"},{"key":"605_CR38","first-page":"1298","volume":"130","author":"N Pemmaraju","year":"2017","unstructured":"\u2022 Pemmaraju N, Kendra S, Lane A, Stein A, Vasu S, Blum W, et al. Results of pivotal phase 2 trial of SL-401 in patients with blastic plasmacytoid dendritic cll neoplasm (BPDCN). Blood. 2017;130:1298 These are early results from a phase 2 study using SL-401 as continuous therapy in BPDCN. This abstract reports high ORR for both first-line and refractory patients. Median OS was not reached in first-line therapy. They also reported 31% CR in the refractory patients.","journal-title":"Blood"},{"issue":"8","key":"605_CR39","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","volume":"2","author":"Y Kovtun","year":"2018","unstructured":"Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Adv. 2018;2(8):848\u201358. \n                      https:\/\/doi.org\/10.1182\/bloodadvances.2018017517\n                      \n                    .","journal-title":"Blood Adv"},{"issue":"8","key":"605_CR40","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","volume":"25","author":"S Arcangeli","year":"2017","unstructured":"Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther. 2017;25(8):1933\u201345. \n                      https:\/\/doi.org\/10.1016\/j.ymthe.2017.04.017\n                      \n                    .","journal-title":"Mol Ther"},{"issue":"15","key":"605_CR41","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343\u201354. \n                      https:\/\/doi.org\/10.1182\/blood-2013-09-529537\n                      \n                    .","journal-title":"Blood"},{"issue":"8","key":"605_CR42","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/leu.2014.62","volume":"28","author":"I Pizzitola","year":"2014","unstructured":"Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, et al. Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28(8):1596\u2013605. \n                      https:\/\/doi.org\/10.1038\/leu.2014.62\n                      \n                    .","journal-title":"Leukemia"},{"key":"605_CR43","doi-asserted-by":"publisher","unstructured":"DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2018. doi: \n                      https:\/\/doi.org\/10.1182\/blood-2018-08-868752\n                      \n                    . blood-2018-08-868752.","DOI":"10.1182\/blood-2018-08-868752"},{"issue":"3","key":"605_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ajh.25000","volume":"93","author":"CD Nardo Di","year":"2018","unstructured":"\u2022 Di Nardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401\u20137. \n                      https:\/\/doi.org\/10.1002\/ajh.25000\n                      \n                    This study used venetoclax in combination with other low-intensity therapies, including HMAs, in patients with relapsed\/refractory myeloid malignancies as well as 2 BPDCN patients. The BPDCN patients both exhibited response to treatment. Overall, the combination regimens were well tolerated.","journal-title":"Am J Hematol"},{"issue":"2","key":"605_CR45","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","volume":"7","author":"J Montero","year":"2017","unstructured":"\u2022 Montero J, Stephansky J, Cai T, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017;7(2):156\u201364. \n                      https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0999\n                      \n                    In this study, the authors report in vivo activity of venetoclax that was dependent on BCL2 activity. They also report use of venetoclax as single-agent therapy in 2 patients with relapsed BPDCN.","journal-title":"Cancer Discov"},{"issue":"51","key":"605_CR46","doi-asserted-by":"publisher","first-page":"e9452","DOI":"10.1097\/MD.0000000000009452","volume":"96","author":"S Grushchak","year":"2017","unstructured":"Grushchak S, Joy C, Gray A, Opel D, Speiser J, Reserva J, et al. Novel treatment of blastic plasmacytoid dendritic cell neoplasm: a case report. Medicine (Baltimore). 2017;96(51):e9452. \n                      https:\/\/doi.org\/10.1097\/MD.0000000000009452\n                      \n                    .","journal-title":"Medicine (Baltimore)"},{"issue":"19","key":"605_CR47","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1158\/1078-0432.CCR-11-0212","volume":"17","author":"A Agliano","year":"2011","unstructured":"Agliano A, Martin-Padura I, Marighetti P, Gregato G, Calleri A, Prior C, et al. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma\/blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2011;17(19):6163\u201373. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0212\n                      \n                    .","journal-title":"Clin Cancer Res"},{"issue":"11","key":"605_CR48","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3324\/haematol.2017.169326","volume":"102","author":"L Philippe","year":"2017","unstructured":"Philippe L, Ceroi A, Bole-Richard E, et al. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2017;102(11):1861\u20138. \n                      https:\/\/doi.org\/10.3324\/haematol.2017.169326\n                      \n                    .","journal-title":"Haematologica"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-019-0605-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0605-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0605-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T23:58:50Z","timestamp":1581983930000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-019-0605-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0605-x","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"4 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"9"}}